www.leiomyosarcoma.org Open in urlscan Pro
104.154.131.198  Public Scan

Form analysis
1 forms found in the DOM

GET https://www.leiomyosarcoma.org/

<form method="get" id="searchform" action="https://www.leiomyosarcoma.org/">
  <div class="row collapse">
    <div class="small-12 columns">
      <input type="text" name="s" id="s" placeholder="search">
      <button type="submit" id="searchsubmit" class="prefix"><i class="fa fa-search"></i></button>
    </div><!-- END of .columns -->
  </div><!-- END of .row.collapse-->
</form>

Text Content

All The Information You Need Concerning
Leiomyosarcoma And Power Morcellators

Contact Us About Us





 * 
 * Menu

 * Leiomyosarcoma
   
   * BACK
   
   * Leiomyosarcoma
   * Leiomyosarcoma Causes
     
     * BACK
     
     * Leiomyosarcoma Causes
     * Fibroid Removal
   * Leiomyosarcoma Symptoms
   * Diagnosis
   * Prognosis
   * Leiomyosarcoma Stages
   * Leiomyosarcoma Survival Rate
   * Leiomyosarcoma Treatment
     
     * BACK
     
     * Leiomyosarcoma Treatment
     * Radiation-Induced Sarcoma
     * Leiomyosarcoma Treatment by Metastatic Site
   * Types of Leiomyosarcoma
     
     * BACK
     
     * Types of Leiomyosarcoma
     * Endomentrial Stromal Sarcoma
     * Metastic Leiomyosarcoma
     * Mesenchymal Chondrosarcoma
     * Malignant Fibrous Histiocytoma
     * MPNST
     * Osteosarcoma
     * Rhabdomyosarcoma
     * Undifferentiated Pleomorph
     * Synovial Sarcoma
   * Life Expectancy
   * Misdiagnosis
 * Power Morcellators
   
   * BACK
   
   * Power Morcellators
   * Surgery
     
     * BACK
     
     * Surgery
     * Power Morcellator Procedures
     * Hysterectomy Cancer
     * Power Morcellator Risks
   * Cancer
     
     * BACK
     
     * Cancer
     * Cancer Incidence
   * Uterine Fibroids
   * Disposable Laparoscopic Morcellator
   * FDA Alert
   * Manufacturers
   * Recalls
 * Resources for Patients
   
   * BACK
   
   * Resources for Patients
   * Doctors
   * Hospitals
   * Support Groups
   * Clinical Trials
   * Leiomyosarcoma Specialists
   * Fibrosarcoma in Humans
   * Alternative Therapies
   * Statistics
   * Leiomyosarcoma Cure
 * Morcellator Lawsuits
   
   * BACK
   
   * Morcellator Lawsuits
   * Uterine Cancer Lawsuits
 * Blog




DIAGNOSED WITH LEIOMYOSARCOMA? GET ANSWERS FAST.

Learn More



DIAGNOSED WITH LEIOMYSARCOMA?

Leiomyosarcoma is considered to be rare, and treatable. It is a cancer of the
soft tissue and involuntary muscle and when it is caught early it can be
effectively removed.


POWER MORCELLATOR ISSUES

With morcellators for gynecological procedures, the most common surgery was the
removal of the uterus (for the purpose of hysterectomy or for myomectomy).


LEIOMYOSARCOMA SUPPORT

Have you or a loved on been diagnosed with Leiomyosarcoma Cancer? Click here for
more information.


LEIOMYOSARCOMA

Leiomyosarcoma (LMS) is a rare form of cancer that most commonly affects the
uterus but can also affect other areas such as the bladder or gastrointestinal
system. It is designated as a “soft tissue sarcoma” and originates in the smooth
or involuntary muscle. LMS is considered malignant cancer and is different from
leiomyoma which is benign. LMS is considered “treatable” when caught early.

LMS is rare, affecting only 6 in 1 million women but is highly aggressive and
likely to metastasize to infect other areas of the body, including the lungs.
Unlike other cancers that affect the uterus, LMS does not usually respond to
hormonal treatments and chemotherapeutic agents or radiation treatments are
sometimes inadequate.

If the leiomyosarcoma cancer is caught in the early stages, the most effective
treatment is generally surgical removal. In order to fully remove the cancer, a
“clear margin” of tissue surrounding the tumor must be removed. This means that
the tumor along with a portion of tissue that appears healthy must be surgically
excised. If any cancer cells are left in the body, a new tumor may begin to
grow.
More than half of all patients treated for LMS require additional treatments
within 8 to 16 months after initial diagnosis.



LAPAROSCOPIC TOOLS

Laparoscopic tools are small tube-like devices such as cameras which can be
inserted into a patient’s abdomen through small incisions. This allows the
surgeon to perform surgery through these small incisions without requiring a
large, open abdominal procedure. Power morcellators were used with other
laparoscopic tools.


FDA INFORMATION

By the end of 2014, most of the medical community had determined that the use of
power morcellation was medically questionable and posed excessive risk to
patients. The FDA has stated that power morcellators should no longer be used
for hysterectomy or myomectomy for patients with fibroids.


SUPPORT

Please contact us if you have any additional questions about power morcellators
or Leiomyosarcoma cancer. Our team of trained professionals are here to help
assist you and your family get the treatment and legal help you deserve.


POWER MORCELLATOR

A power morcellator is a surgical device that has been used for gynecological
surgical procedures. It was intended to remove tumors, and diseased tissue or
organs through minimally invasive surgery. Though it was designed to reduce risk
to the patients, its use may also spread cancer cells when tumors are removed.

A power morcellator is inserted into the abdominal cavity through a small
incision similar to incisions used for laparoscopic surgery. The power
morcellator then “shreds” the tissue to be removed which is then suctioned out
of the abdomen without the need for a large abdominal incision.

Power morcellators were invented to remove a variety of tumors and other
diseased tissue and organs such as renal tumors, but have most commonly been
used for removal of the uterus. They have been used in a number of myomectomies
and hysterectomies for reasons such as fibroid tumors and other gynecological
problems including diagnosed or undiagnosed leiomyosarcoma.

Results have shown that the use of a power morcellator may spread tumors by
leaving cells of the shredded tissue behind. In the case of benign tumors such
as fibroids, new fibroid tumors may begin to grow in other areas creating
medical difficulties. In the case of leiomyosarcoma, new sarcoma cancers which
are malignant will spread, making treatment of the deadly disease much more
difficult.

Unfortunately, the occurrence of leiomyosarcoma may be unidentified or hidden
until a surgical removal occurs. Use of power morcellation makes the spread of
leiomyosarcoma much more likely.

Cancer, including leiomyosarcoma that has been spread through power morcellation
can affect any organ in the abdominal cavity including the liver, kidneys,
bladder, intestines or abdominal wall. Cancer cells that have been shed due to
morcellation can potentially enter the blood or lymphatic system and travel to
other parts of the body such as the bones, lungs, heart or brain.

The five-year survival rate for patients with leiomyosarcoma is dramatically
decreased if the cancer has spread and is only 4 to 16 percent.


MORE INFORMATION ON MORCELLATORS & LEIOMYOSARCOMA

However, by 2009, the medical authorities were not advocating for the use of
morcellators at all. Instead, they insisted that the equally minimally invasive
vaginal hysterectomy was preferable to the any other procedure. Though the ACOG
(American College of Obstetricians and Gynecologists) did not come out against
the use of morcellators, it did say that in the case of benign disease, the
vaginal procedure had the best outcome with fewer complications than other
surgical options.

JOSEPH EVANS

Leiomyosarcoma Information


FBI INVESTIGATING MEDICAL DEVICE THAT SPREAD CANCER IN WOMEN

The Federal Bureau of Investigation has reportedly launched an investigation
into a medical device that has been commonplace in uterine surgeries for years.
Investigators are especially interested in Johnson & Johnson, once the largest
manufacturer of this tool. Their corner... Read More


HYSTERECTOMY DEVICE WILL BE COVERED BY INSURER DESPITE DANGER OF UTERINE
CANCER’S SPREAD

The fourth-largest health insurer in the country, Health Care Service Corp.,
will continue covering laparoscopic power morcellators. This, despite the fact
that they were previously considering a policy that would have curtailed the use
of these surgical tools which have... Read More


MAIN LINKS

 * Drugs and Device
 * Life Expectancy
 * Clinical Trials
 * Health Info
 * News


CONTACT US





THIS WEBSITE IS A PAID LEGAL ADVERTISMENT. ATTORNEY JEFF MEYER IS RESPONSIBLE
FOR THE CONTENT OF THIS ADVERTISMENT.JEFF MEYER IS LICENSED IN TEXAS AND
CALIFORNIA. CONSULT A DOCTOR ON ALL MEDICAL DECISIONS.WRITTEN INFORMATION IS
AVAILABLE ON REQUEST. ONCE YOU BECOME A CLIENT OF THE FIRM, INFORMATION
REGARDING YOUR CLAIM MAY BE TRANSMITTED IN COMPLIANCE WITH HIPAA AND HOUSE BILL
300. THE MEYER LAW FIRM WILL MAINTAIN JOINT REPRESENTATION AND JOINT
RESPONSIBILITY FOR CLIENTS AND CASES,BUT CASES AND CLIENTS WILL LIKELY BE
REFERRED TO OTHER LAW FIRMS FOR PRINCIPAL HANDLING. LEGAL REPRESENTATION IS NOT
OFFERED OR AVAILABLE IN TENNESSEE. BY USING THIS WEBSITE, YOU AGREE TO OUR
PRIVACY POLICYANDTERMS OF USE.MAIN OFFICE; HOUSTON, TEXAS.



[contact-form-7 id="262" title="Modal Form"]